Exabis Library
Welcome to the e-CCO Library!
P342: Maladaptive coping, self-efficacy and patient reported outcomes in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P342: Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P342: Treatment experience of perianal fistulising Crohn's disease: a systematic literature review
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P342: Tryptophan as a biomarker for the course of IBD and anti-TNF α response
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P343 Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P343: Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAID
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P343: Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P343: Eosinophilic inflammation as an indicator of the activity of the course of Inflammatory Bowel Diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P343: Female gender, somatization and presence of IBS-type symptoms predicts Dyspareunia in patients with IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P343: Levels of the anticoagulant and anti-inflammatory protein S (PROS1) in patients with inflammatory bowel disease (IBD) relationship with disease activity, IBD disease patterns, and C4-binding protein (C4BP)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P343: Maintenance of deep remission in Crohn’s disease after switching from anti–TNF to ustekinumab.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P343: The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease and the relationship with biochemical markers of disease activity
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P344: Diverting ileostomy in Inflammatory Bowel Disease's surgery: the real clinical cost analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P344: Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P344: Epidemiology of clostridium difficile infections in IBD over two decades
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P344: Non-adherence to medical therapy is associated with hospitalisations and the development of active disease in inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P344: Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P344: Vitamin D-Induced alterations in Cytokine levels lower the risk of clinical relapse in ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P344: What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM